Home › Compare › UNRIF vs ABBV
UNRIF yields 217.86% · ABBV yields 3.06%● Live data
📍 UNRIF pulled ahead of the other in Year 1
Combined, UNRIF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of UNRIF + ABBV for your $10,000?
United Company RUSAL, International Public Joint-Stock Company produces and sells aluminum and related products. It operates through four segments: Aluminium, Alumina, Energy, and Mining and Metals. The company is involved in the mining and refining of bauxite and nepheline ore into alumina; the smelting of primary aluminum from alumina; and the fabrication of aluminum and aluminum alloys into semi-fabricated and finished products. Its products include primary aluminum, billets, rolling slabs, primary foundry alloys, wire rods, high-purity aluminum, foil and packaging products, aluminum wheels and powders, alumina and bauxite products, corundum products, and gallium and silicon products, as well as aluminum anodes for cathodic protection. The company is also involved in the mining and sale of coal; generation and transmission of electricity produced from various sources; and trading businesses. In addition, it offers repair and maintenance, and finance services. The company sells its products primarily in Europe, Russia, other countries of the Commonwealth of Independent States, Asia, and North and South America. The company was founded in 2000 and is based in Kaliningrad, Russia. United Company RUSAL, International Public Joint-Stock Company is a subsidiary of En+ GROUP International public joint-stock company.
Full UNRIF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.